{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:49:27Z","timestamp":1788997767392,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1K23GM128221-01A1"],"award-info":[{"award-number":["1K23GM128221-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1P30DK111024-01"],"award-info":[{"award-number":["1P30DK111024-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11892-019-1184-8","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T03:41:56Z","timestamp":1564371716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Debate on Insulin vs Non-insulin Use in the Hospital Setting\u2014Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?"],"prefix":"10.1007","volume":"19","author":[{"given":"Francisco J.","family":"Pasquel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Fayfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"issue":"1","key":"1184_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2011-2098","volume":"97","author":"Guillermo E. Umpierrez","year":"2012","unstructured":"Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16\u201338.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"6","key":"1184_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2337\/dc09-9029","volume":"32","author":"E. S. Moghissi","year":"2009","unstructured":"Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119\u201331.","journal-title":"Diabetes Care"},{"issue":"3","key":"1184_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","volume":"87","author":"Guillermo E. Umpierrez","year":"2002","unstructured":"Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978\u201382.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"1184_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2337\/dc10-0304","volume":"33","author":"A. Frisch","year":"2010","unstructured":"Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care. 2010;33(8):1783\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"1184_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3810\/hp.2011.04.397","volume":"39","author":"Francisco J. Pasquel","year":"2011","unstructured":"Pasquel FJ, Smiley D, Spiegelman R, Lin E, Peng L, Umpierrez GE. Hyperglycemia is associated with increased hospital complications and mortality during parenteral nutrition. Hosp Pract (Minneap). 2011;39(2):81\u20138.","journal-title":"Hospital Practice"},{"issue":"15","key":"1184_CR6","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.290.15.2041","volume":"290","author":"SJ Finney","year":"2003","unstructured":"Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. Jama. 2003;290(15):2041\u20137.","journal-title":"Jama"},{"issue":"1","key":"1184_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/SLA.0000000000000688","volume":"261","author":"Meera Kotagal","year":"2015","unstructured":"Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg. 2015;261(1):97\u2013103.","journal-title":"Annals of Surgery"},{"issue":"5","key":"1184_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.jvca.2011.12.016","volume":"26","author":"Jie Hua","year":"2012","unstructured":"Hua J, Chen G, Li H, Fu SK, Zhang LM, Scott M, et al. Intensive intraoperative insulin therapy versus conventional insulin therapy during cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2012;26(5):829\u201334.","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"issue":"7","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.mayocp.2017.04.015","volume":"92","author":"James S. Krinsley","year":"2017","unstructured":"Krinsley JS, Maurer P, Holewinski S, et al. Glucose control, diabetes status, and mortality in critically ill patients: The Continuum From Intensive Care Unit Admission to Hospital Discharge. Mayo Clin Proc. 2017;92(7):1019\u201329.","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"1184_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/SLA.0b013e31827b6bbc","volume":"257","author":"Steve Kwon","year":"2013","unstructured":"Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann Surg. 2013;257(1):8\u201314.","journal-title":"Annals of Surgery"},{"issue":"2","key":"1184_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/dc10-1407","volume":"34","author":"G. E. Umpierrez","year":"2011","unstructured":"Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. Feb 2011;34(2):256\u201361.","journal-title":"Diabetes Care"},{"issue":"9","key":"1184_CR12","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2337\/dc15-0303","volume":"38","author":"Guillermo Umpierrez","year":"2015","unstructured":"Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care. Sep 2015;38(9):1665\u201372.","journal-title":"Diabetes Care"},{"issue":"19","key":"1184_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa011300","volume":"345","author":"Greet Van den Berghe","year":"2001","unstructured":"van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19):1359\u201367.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"1184_CR14","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.2337\/dc13-1771","volume":"37","author":"Takehiro Okabayashi","year":"2014","unstructured":"Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care. 2014;37(6):1516\u201324.","journal-title":"Diabetes Care"},{"key":"1184_CR15","doi-asserted-by":"crossref","unstructured":"Kyi M, Colman PG, Wraight PR, et al. Early Intervention for Diabetes in Medical and Surgical Inpatients Decreases Hyperglycemia and Hospital-Acquired Infections: A Cluster Randomized Trial. Diabetes Care. 2019;42(5):832\u201340.","DOI":"10.2337\/dc18-2342"},{"issue":"2","key":"1184_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2337\/diacare.27.2.553","volume":"27","author":"S. Clement","year":"2004","unstructured":"Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553\u201397.","journal-title":"Diabetes Care"},{"issue":"2","key":"1184_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1210\/jc.2008-1441","volume":"94","author":"Guillermo E. Umpierrez","year":"2009","unstructured":"Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(2):564\u20139.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"9","key":"1184_CR18","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2337\/dc07-0295","volume":"30","author":"G. E. Umpierrez","year":"2007","unstructured":"Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181\u20136.","journal-title":"Diabetes Care"},{"key":"1184_CR19","doi-asserted-by":"crossref","unstructured":"American Diabetes A. 14. Diabetes care in the hospital: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S144\u201351.","DOI":"10.2337\/dc18-S014"},{"issue":"8","key":"1184_CR20","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2337\/dc12-1988","volume":"36","author":"G. E. Umpierrez","year":"2013","unstructured":"Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169\u201374.","journal-title":"Diabetes Care"},{"issue":"7","key":"1184_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2337\/dc08-2127","volume":"32","author":"A Turchin","year":"2009","unstructured":"Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32(7):1153\u20137.","journal-title":"Diabetes Care"},{"issue":"12","key":"1184_CR22","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1111\/dme.12002","volume":"29","author":"K Nirantharakumar","year":"2012","unstructured":"Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, Coleman JJ. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabet Med. 2012;29(12):e445\u20138.","journal-title":"Diabet Med"},{"issue":"7","key":"1184_CR23","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.2337\/dc12-2233","volume":"36","author":"GE Umpierrez","year":"2013","unstructured":"Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36(7):2112\u20137.","journal-title":"Diabetes Care"},{"key":"1184_CR24","doi-asserted-by":"crossref","unstructured":"Umpierrez GE, Schwartz S. Use of incretin-based therapy in hospitalized patients with hyperglycemia. 2014;20(9):933\u201344.","DOI":"10.4158\/EP13471.RA"},{"issue":"11","key":"1184_CR25","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.2337\/dc13-0277","volume":"36","author":"G. E. Umpierrez","year":"2013","unstructured":"Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430\u20135.","journal-title":"Diabetes Care"},{"issue":"4","key":"1184_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/dom.13587","volume":"21","author":"Priyathama Vellanki","year":"2018","unstructured":"Vellanki P, Rasouli N, Baldwin D, et al. Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial. Diabetes Obes Metab. 2018 Nov 20. https:\/\/doi.org\/10.1111\/dom.13587 .","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"1","key":"1184_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2017-000394","volume":"5","author":"R Garg","year":"2017","unstructured":"Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5(1):e000394.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"1184_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/jcm7090271","volume":"7","author":"Luis P\u00e9rez-Belmonte","year":"2018","unstructured":"Perez-Belmonte LM, Gomez-Doblas JJ, Millan-Gomez M, et al. Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). J Clin Med. 2018;7(9):271.","journal-title":"Journal of Clinical Medicine"},{"issue":"3","key":"1184_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2337\/dc18-1760","volume":"42","author":"Maya Fayfman","year":"2019","unstructured":"Fayfman M, Galindo RJ, Rubin DJ, et al. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care. 2019;42(3):450\u201356. This pilot clinical trial suggested that exenatide alone or in combination with basal insulin is safe and effective for the management of hospitalized general medical and surgical patients with T2D.","journal-title":"Diabetes Care"},{"issue":"2","key":"1184_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2213-8587(16)30402-8","volume":"5","author":"FJ Pasquel","year":"2017","unstructured":"Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125\u201333. This study showed most patients with mild to moderate hyperglycemia can effectively be treated with basal insulin along with a DPP-4 inhibitor in the hospital.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1184_CR31","first-page":"91","volume":"7","author":"L Montejano","year":"2016","unstructured":"Montejano L, Vo L, McMorrow D. Transitions of care for people with type 2 diabetes: utilization of antihyperglycemic agents pre- and post-hospitalization. Diagn Ther. 2016;7(1):91\u2013103.","journal-title":"Diagn Ther"},{"key":"1184_CR32","doi-asserted-by":"crossref","unstructured":"Bishay RH, Meyerowitz-Katz G, Chandrakumar D, Jayaballa R, Hng TM, Mclean M, et al. Evaluating the diabetes-cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney\u2019s \u2018diabetes hotspot\u2019 and the establishment of a novel model of care. Diabetol Metab Syndr. 2018;10:90.","DOI":"10.1186\/s13098-018-0393-7"},{"issue":"3","key":"1184_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4103\/0975-7406.175975","volume":"8","author":"SV Satpathy","year":"2016","unstructured":"Satpathy SV, Datta S, Upreti B. Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. J Pharm Bioallied Sci. 2016;8(3):223\u20138.","journal-title":"J Pharm Bioallied Sci"},{"issue":"7","key":"1184_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005165","volume":"4","author":"R Rajendran","year":"2014","unstructured":"Rajendran R, Kerry C, Rayman G, GICsg M. Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes. BMJ Open. 2014;4(7):e005165.","journal-title":"BMJ Open"},{"issue":"3","key":"1184_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2710.2009.01080.x","volume":"35","author":"G Sultana","year":"2010","unstructured":"Sultana G, Kapur P, Aqil M, Alam MS, Pillai KK. Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J Clin Pharm Ther. 2010;35(3):267\u201377.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1184_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.QMH.0000344595.48510.cb","volume":"18","author":"DW Scotton","year":"2009","unstructured":"Scotton DW, Wierman H, Coughlan A, Walters M, Kuhn C. Assessing the appropriate use of metformin in an inpatient setting and the effectiveness of two pharmacy-based measures to improve guideline adherence. Qual Manag Health Care. 2009;18(1):71\u20136.","journal-title":"Qual Manag Health Care"},{"issue":"1","key":"1184_CR37","first-page":"170","volume":"29","author":"HM Sharabash","year":"2006","unstructured":"Sharabash HM, Remington TL, Mar P, Winston R, Walker PC. Retrospective review of metformin in inpatients and outpatients at the University of Michigan. Diabetes Care. Jan 2006;29(1):170\u20131.","journal-title":"Diabetes Care"},{"issue":"7","key":"1184_CR38","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00268-016-3469-2","volume":"40","author":"T Haltmeier","year":"2016","unstructured":"Haltmeier T, Benjamin E, Beale E, Inaba K, Demetriades D. Insulin-treated patients with diabetes mellitus undergoing emergency abdominal surgery have worse outcomes than patients treated with oral agents. World J Surg. 2016;40(7):1575\u201382.","journal-title":"World J Surg"},{"issue":"5","key":"1184_CR39","first-page":"520","volume":"62","author":"N Waki","year":"2012","unstructured":"Waki N, Memon A, Khan MO, et al. Current understanding of treatment and management protocol for adult diabetic in-patients at a tertiary care hospital. J Pak Med Assoc. 2012;62(5):520\u20134.","journal-title":"J Pak Med Assoc"},{"issue":"5","key":"1184_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4103\/0250-474X.45404","volume":"70","author":"S Vengurlekar","year":"2008","unstructured":"Vengurlekar S, Shukla P, Patidar P, Bafna R, Jain S. Prescribing pattern of antidiabetic drugs in Indore city hospital. Indian J Pharm Sci. 2008;70(5):637\u201340.","journal-title":"Indian J Pharm Sci"},{"issue":"10","key":"1184_CR41","first-page":"648","volume":"96","author":"C Kodner","year":"2017","unstructured":"Kodner C, Anderson L, Pohlgeers K. Glucose management in hospitalized patients. Am Fam Physician. 2017;96(10):648\u201354.","journal-title":"Am Fam Physician"},{"issue":"6","key":"1184_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4158\/EP-2018-0036","volume":"24","author":"Roma Y. Gianchandani","year":"2018","unstructured":"Gianchandani RY, Pasquel FJ, Rubin DJ, Dungan KM, Vellanki P, Wang H, et al. The efficacy and safety of co-administration of sitagliptin with metformin in patients with type 2 diabetes at hospital discharge. Endocr Pract. 2018;24(6):556\u201364.","journal-title":"Endocrine Practice"},{"issue":"10","key":"1184_CR43","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00268-013-2086-6","volume":"37","author":"E Karamanos","year":"2013","unstructured":"Karamanos E, Sivrikoz E, Beale E, Chan L, Inaba K, Demetriades D. Effect of diabetes on outcomes in patients undergoing emergent cholecystectomy for acute cholecystitis. World J Surg. 2013;37(10):2257\u201364.","journal-title":"World J Surg"},{"issue":"3","key":"1184_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MAJ.0b013e3182a562b7","volume":"349","author":"FJ Pasquel","year":"2015","unstructured":"Pasquel FJ, Klein R, Adigweme A, et al. Metformin-associated lactic acidosis. Am J Med Sci. 2015;349(3):263\u20137.","journal-title":"Am J Med Sci"},{"issue":"7506","key":"1184_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature13270","volume":"510","author":"Anila K. Madiraju","year":"2014","unstructured":"Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542\u20136.","journal-title":"Nature"},{"issue":"9","key":"1184_CR46","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41591-018-0125-4","volume":"24","author":"Anila K. Madiraju","year":"2018","unstructured":"Madiraju AK, Qiu Y, Perry RJ, Rahimi Y, Zhang XM, Zhang D, et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med. Sep 2018;24(9):1384\u201394.","journal-title":"Nature Medicine"},{"key":"1184_CR47","doi-asserted-by":"crossref","unstructured":"Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;14(4):CD002967.","DOI":"10.1002\/14651858.CD002967.pub3"},{"key":"1184_CR48","unstructured":"FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM494140.pdf Accessed April 6, 2019."},{"issue":"2","key":"1184_CR49","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.016","volume":"25","author":"Yohei Mima","year":"2016","unstructured":"Mima Y, Kuwashiro T, Yasaka M, Tsurusaki Y, Nakamura A, Wakugawa Y, et al. Impact of metformin on the severity and outcomes of acute ischemic stroke in patients with type 2 diabetes mellitus. J Stroke Cerebrovasc Dis. 2016;25(2):436\u201346.","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"issue":"1","key":"1184_CR50","first-page":"e3929","volume":"11","author":"BN Sarfo-Adu","year":"2019","unstructured":"Sarfo-Adu BN, Hendley JL, Pick B, Oyibo SO. Glycemic control during enteral tube feeding in patients with diabetes mellitus. Cureus. 2019;11(1):e3929.","journal-title":"Cureus"},{"key":"1184_CR51","doi-asserted-by":"publisher","first-page":"3545914","DOI":"10.1155\/2016\/3545914","volume":"2016","author":"M Lepelley","year":"2016","unstructured":"Lepelley M, Giai J, Yahiaoui N, Chanoine S, Villier C. Lactic acidosis in diabetic population: is metformin implicated? Results of a matched case-control study performed on the type 2 diabetes population of Grenoble Hospital University. J Diabetes Res. 2016;2016:3545914.","journal-title":"J Diabetes Res"},{"issue":"4","key":"1184_CR52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.10.019","volume":"26","author":"Georgios Tsivgoulis","year":"2017","unstructured":"Tsivgoulis G, Goyal N, Iftikhar S, Zand R, Chang JJ, Elijovich L, et al. Sulfonylurea pretreatment and in-hospital use does not impact acute ischemic strokes (AIS) outcomes following intravenous thrombolysis. J Stroke Cerebrovasc Dis. 2017;26(4):795\u2013800.","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"issue":"9","key":"1184_CR53","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1161\/STROKEAHA.107.482216","volume":"38","author":"Hagen Kunte","year":"2007","unstructured":"Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38(9):2526\u201330.","journal-title":"Stroke"},{"issue":"4","key":"1184_CR54","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/STROKEAHA.118.022301","volume":"50","author":"H Irvine","year":"2019","unstructured":"Irvine H, Male S, Robertson J, Bell C, Bentho O, Streib C. Reduced intracerebral hemorrhage and perihematomal edema volumes in diabetics on sulfonylureas. Stroke. 2019;50(4):995\u20138.","journal-title":"Stroke"},{"issue":"3","key":"1184_CR55","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.3390\/ijms16034973","volume":"16","author":"N Caffes","year":"2015","unstructured":"Caffes N, Kurland DB, Gerzanich V, Simard JM. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int J Mol Sci. 2015;16(3):4973\u201384.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1184_CR56","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/ph6101287","volume":"6","author":"David Kurland","year":"2013","unstructured":"Kurland DB, Tosun C, Pampori A, et al. Glibenclamide for the treatment of acute CNS injury. Pharmaceuticals (Basel). 2013;6(10):1287\u2013303.","journal-title":"Pharmaceuticals"},{"issue":"8","key":"1184_CR57","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/NEN.0000000000000223","volume":"74","author":"Rupal I. Mehta","year":"2015","unstructured":"Mehta RI, Tosun C, Ivanova S, Tsymbalyuk N, Famakin BM, Kwon MS, et al. Sur1-Trpm4 cation channel expression in human cerebral infarcts. J Neuropathol Exp Neurol. 2015;74(8):835\u201349.","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"7","key":"1184_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/j.1875-9114.2011.01088.x","volume":"32","author":"CM Deusenberry","year":"2012","unstructured":"Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613\u20137.","journal-title":"Pharmacotherapy."},{"issue":"10","key":"1184_CR59","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/dme.13409","volume":"34","author":"K. Stuart","year":"2017","unstructured":"Stuart K, Adderley NJ, Marshall T, Rayman G, Sitch A, Manley S, et al. Predicting inpatient hypoglycaemia in hospitalized patients with diabetes: a retrospective analysis of 9584 admissions with diabetes. Diabetic Med. 2017;34(10):1385\u201391.","journal-title":"Diabetic Medicine"},{"key":"1184_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12902-016-0084-z","volume":"16","author":"PC Heaton","year":"2016","unstructured":"Heaton PC, Desai VC, Kelton CM, Rajpathak SN. Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes. BMC Endocr Disord. 2016;16:4.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"1184_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1515\/jbcpp-2012-0012","volume":"23","author":"A Khalam","year":"2012","unstructured":"Khalam A, Dilip C, Shinu C. Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital. J Basic Clin Physiol Pharmacol. 2012;23(4):173\u20137.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"6","key":"1184_CR62","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","volume":"147","author":"Shari Bolen","year":"2007","unstructured":"Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386\u201399.","journal-title":"Annals of Internal Medicine"},{"issue":"4\u20135","key":"1184_CR63","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11064-006-9138-3","volume":"32","author":"J Lee","year":"2007","unstructured":"Lee J, Reding M. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem Res. 2007;32(4\u20135):635\u20138.","journal-title":"Neurochem Res"},{"key":"1184_CR64","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 7 2016;374(14):1321\u201331."},{"issue":"2","key":"1184_CR65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/00325481.2015.996504","volume":"127","author":"Stanley S. Schwartz","year":"2014","unstructured":"Schwartz SS, DeFronzo RA, Umpierrez GE. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. Postgrad Med. 2015;127(2):251\u20137.","journal-title":"Postgraduate Medicine"},{"issue":"1","key":"1184_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1517\/17425255.2013.731394","volume":"9","author":"Maria J Jespersen","year":"2012","unstructured":"Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9(1):17\u201329.","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"19","key":"1184_CR67","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"Steven P. Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"1184_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"Steven P. Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"New England Journal of Medicine"},{"key":"1184_CR69","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u2013130.","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"1184_CR70","doi-asserted-by":"crossref","unstructured":"Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","DOI":"10.1016\/S0140-6736(18)32261-X"},{"issue":"1","key":"1184_CR71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4158\/EP12196.OR","volume":"19","author":"Mohammad Abuannadi","year":"2013","unstructured":"Abuannadi M, Kosiborod M, Riggs L, House J, Hamburg M, Kennedy K, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract. 2013;19(1):81\u201390.","journal-title":"Endocrine Practice"},{"issue":"3","key":"1184_CR72","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.jvca.2013.06.021","volume":"28","author":"Benjamin A. Kohl","year":"2014","unstructured":"Kohl BA, Hammond MS, Cucchiara AJ, Ochroch EA. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study. J Cardiothorac Vasc Anesth. 2014;28(3):618\u201325.","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"issue":"5","key":"1184_CR73","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/ALN.0000000000001838","volume":"127","author":"Guillaume Besch","year":"2017","unstructured":"Besch G, Perrotti A, Mauny F, Puyraveau M, Baltres M, Flicoteaux G, et al. Clinical effectiveness of intravenous exenatide infusion in perioperative glycemic control after coronary artery bypass graft surgery: a phase II\/III randomized trial. Anesthesiology. 2017;127(5):775\u201387.","journal-title":"Anesthesiology"},{"issue":"3","key":"1184_CR74","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/anae.14180","volume":"73","author":"J. A. W. Polderman","year":"2017","unstructured":"Polderman JAW, van Steen SCJ, Thiel B, Godfried MB, Houweling PL, Hollmann MW, et al. Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. Anaesthesia. 2018;73(3):332\u20139. Findings from this study suggest GLP-1RA can improve glycemic control in the perioperative period.","journal-title":"Anaesthesia"},{"issue":"12","key":"1184_CR75","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.2337\/dc15-1835","volume":"38","author":"Francisco J. Pasquel","year":"2015","unstructured":"Pasquel FJ, Gomez-Huelgas R, Anzola I, Oyedokun F, Haw JS, Vellanki P, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care. 2015;38(12):e202\u20133.","journal-title":"Diabetes Care"},{"issue":"6","key":"1184_CR76","doi-asserted-by":"publisher","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"Thomas Nystr\u00f6m","year":"2004","unstructured":"Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209\u201315.","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"2","key":"1184_CR77","first-page":"288","volume":"5","author":"Jacob L\u00f8nborg","year":"2012","unstructured":"Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5(2):288\u201395.","journal-title":"Circulation: Cardiovascular Interventions"},{"issue":"9","key":"1184_CR78","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"George G. Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694\u20139.","journal-title":"Journal of Cardiac Failure"},{"issue":"4","key":"1184_CR79","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-011-2440-x","volume":"55","author":"D Nathanson","year":"2012","unstructured":"Nathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926\u201335.","journal-title":"Diabetologia"},{"issue":"5","key":"1184_CR80","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","volume":"100","author":"George G. Sokos","year":"2007","unstructured":"Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100(5):824\u20139.","journal-title":"The American Journal of Cardiology"},{"issue":"8","key":"1184_CR81","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"Lazaros A. Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962\u20135.","journal-title":"Circulation"},{"key":"1184_CR82","doi-asserted-by":"crossref","unstructured":"Besch G, Perrotti A, Salomon du Mont L, Puyraveau M, Ben-Said X, Baltres M, et al. Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II\/III ExSTRESS randomized trial. Cardiovasc Diabetol. 2018;17(1):140.","DOI":"10.1186\/s12933-018-0784-y"},{"issue":"4","key":"1184_CR83","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1186\/cc9222","volume":"14","author":"Gabriel A Mecott","year":"2010","unstructured":"Mecott GA, Herndon DN, Kulp GA, Brooks NC, al-Mousawi AM, Kraft R, et al. The use of exenatide in severely burned pediatric patients. Crit Care. 2010;14(4):R153.","journal-title":"Critical Care"},{"issue":"6","key":"1184_CR84","doi-asserted-by":"publisher","first-page":"e022189","DOI":"10.1136\/bmjopen-2018-022189","volume":"8","author":"Abraham H Hulst","year":"2018","unstructured":"Hulst AH, Visscher MJ, Godfried MB, Thiel B, Gerritse BM, Scohy TV, et al. Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery. BMJ Open. 2018;8(6):e022189.","journal-title":"BMJ Open"},{"issue":"1","key":"1184_CR85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"22","key":"1184_CR86","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Bernard Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"1184_CR87","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Bruce Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"1184_CR88","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"Ngozi Erondu","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680\u20136.","journal-title":"Diabetes Care"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-019-1184-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T16:39:20Z","timestamp":1695055160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-019-1184-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s11892-019-1184-8","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"29 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Francisco J. Pasquel has received consulting fees and research support from Merck, and consulting fees from Boehringer Ingelheim, Lilly, and AstraZeneca.Maya Fayfman declares no conflicts of interest.Guillermo E. Umpierrez has received unrestricted research support for inpatient studies (to Emory University) from Merck, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Informed consent was obtained from all individual participants included in the studies performed by the authors. This article does not contain any animal studies performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"65"}}